Диссертация (1140119), страница 23
Текст из файла (страница 23)
– 1999. – Т. 232.69. Юрьева О. П. О типах дизонтогенеза у детей, больных шизофренией//Журн. невропатол. и психиатр. – 1970. – Т. 70. – №. 8. – С. 1229-1235.70. ЯстребовВ.С.Клинико-эпидемиологическаяхарактеристиканегоспитализированных больных шизофренией. Журн. невропатол. и психиатр.1987. – 87(8). – С.1207-1215.71. Addington D.D., Azorin J.M., Fallon I.R.H. et al.
Clinical issues related todepression in schizophrenia: an international survey of psychiatrists. Acta PsychiatrScand 2002; 105: 189-195.72. Addington D., Addington J., Atkinson M. A psychometric comparison ofthe Calgary depression scale for schizophrenia and the Hamilton depression rating scale//Schizophrenia research. – 1996. – Т. 19. – №. 2.
– С. 205-212.12373. Addington D., Addington J., Maticka-Tyndale E. Assessing depression inschizophrenia: the Calgary Depression Scale //The British journal of psychiatry. – 1993.74. Addington D. et al. Reliability and validity of a depression rating scale forschizophrenics //Schizophrenia research. – 1992. – Т. 6. – №. 3.
– С. 201-208.75. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability andvalidity of a depression rating scale for schizophrenics.// Schizophr Res. 1992; 6: 201208.76. Addington DE, Mohamed S, Rosenheck RA, et al. Impact ofsecondgeneration antipsychotics and perphenazine on depressive symptoms in arandomized trial of treatment for chronic schizophrenia. J Clin Psychiatry 2011.
– Vol.72.– P.75-80.77. Alnaes R., Torgensen S. Personality and personality disorders amongpatients with major depression in combination with dysthymic or cyclothymic disorders.// 1989. - Acta Psychiatr. Stand. Vol.79. - P.363-369.78. Amminger G.P., Resch F., Mutschlecher R. et al. Premorbid adjustment andremission of positive symptoms in first-episode psychosis // Eur.
Child Adolesc.Psychiatry. 1997. Vol. 6. P. 212–218.79. Aono T, Kaneko M, Numata Y, Takahashi Y, Yamamoto T, Kumashiro H.Effects of amoxapine, a new antidepressant, on pseudoneurotic schizophrenia. // FoliaPsychiatr Neurol Jpn. 1981. – Vol.35(2). – P.115-12180. Barbee J, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine,risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistantmajor depressive disorder.
// Acta Psychiatr Scand. 2004. – Vol.. – P.975–981.81. Baune B.T. New developments in the management of major depressivedisorder and generalized anxiety disorder: role of quetiapine // Neuropsychiatr Dis Treat.2008. – Vol.4(6). – P.1181–1191.82. Bellini L., Gatti F., Gasperini M., Smeraldi E. A comparison betweendelusional and non-delusional depressives. // Journal of Affective Disorders 1992. –Vol.25. – P.129–138.12483. Bergman A.J., Harvey P.D., Roitman S.L. et al.Verbal learning and memoryin schizotypal personality disorder // Schizophr. Bull.
– 1998. – Vol. 24(4). – P. 635–641.84. Bieling PJ, MacQueen GM, Marriot MJ, Robb JC, Begin H, Joffe RT, YoungLT. Longitudinal outcome in patients with bipolar disorder assessed by life-charting isinfluenced by DSM-IV personality disorder symptoms. // Bipolar Disord. 2003. –Vol.5(1). P.14-21.85. Birchwood M. et al. Depression, demoralization and control over psychoticillness: a comparison of depressed and non-depressed patients with a chronic psychosis//Psychological medicine.
– 1993. – Т. 23. – №. 2. – С. 387-395.86. Bosanac P., Castle D. Schizophrenia and depression. Medical Journal ofAustralia. 2012. – Vol.1(4). – P.36–39.87. Black D.W., Bell S., Hulbert, J. Nasrallah, A. The importance of axis II inpatients with major depression: a controlled study. // Affect. Disord. 1998. – Vol.14.
–P.115- 122.88. Blier P. Medication Combination and Augmentation Strategies in theTreatment of Major Depression. Washington, DC: American Psychiatric Publishing, Inc.,200689. Blier P., Szabo S.T. Potential mechanisms of action of atypical antipsychoticmedications in treatmentresistant depression and anxiety // J. Clin.
Psychiatry. 2005. Vol.66 (8). – P.30-40.90. Brebion G., Amador X., Smith M., Malaspina D., Sharif Z., Gorman J.M.Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia.- Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 2000; Vol. 13, No 3, p.177-183.91.
Brieger P, Ehrt U, Marneros A. Frequency of comorbid personality disordersin bipolar and unipolar affective disorders. Compr Psychiatry. 2003. – Vol.44. – P.28-34.– P.20.12592. Brieger Р., Ehrt U., Bloenk R., Marneros A. Consequences of comorbidpersonality disorders in major depression // J. Nerv. Ment. Dis. 2002. - Vol.190(5). P.304–309.93. Browne S., Larkin C., O'Callaghar E. Outcome studies in schizophrenia //Irish J.
Psychol. Med. - 1999. - Vol. 16. - № 4. - Рр.140-144.94. Buckley P. F. et al. Psychiatric comorbidities and schizophrenia//Schizophrenia bulletin. – 2008. – Т. 35. – №. 2. – С. 383-402.95. Cadenhead K.S., Light G.A., Geyer M.A., McDowell J.E., Braff D.L.Neurobiological measures of schizotypal personality disorder: defining an inhibitoryendophenotype? // Am.
J. Psychiatry/. 2002. - Vol.159. – P.869–87196. Cadenhead K, Light G, Geyer M, Braff D. Sensory gating deficits assessedby the P50 event-related potential in subjects with schizotypal personality disorder. AmJ Psychiatry 2000. – Vol.157(1). – P.55–59.97. Caldwell C.B., Gottesman I.I. Schizophrenics kill themselves too: a reviewof risk factors for suicide /// Schizophr. Bull. 1990. - Vol.16. - P.571–589.98.
Coid J, Yang M, Tyerer P, et al. Prevalence and correlates of personalitydisorder in Great Britain. Br J Psychiatry 2006. – Vol.188. – P.423–431.99. Corruble E, Ginestet D, Guelfi JD. Comorbidity of personality disorders andunipolar major depression: A review References. // J Affect Disord. 1996. – 12. –Vol.37(2-3). – P.157-170.100. Cowen PJ. New drugs, old problems.
Revisiting... Pharmacologicalmanagement of treatment-resistant depression. Advances in Psychiatric Treatment 2005;11.101. Crow T. J. The two-syndrome concept: original and current status. //Schizophrenia bulletin. –1985. – Vol.11(3). – P.475-485.102. Daniel DG, Zimbroff DL, Potkin SG et al. Ziprasidone 80 mg/day and 160mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6Week Placebo-Controlled Trial.
// Neuropsychopharmacology 1999. Vol.20 (5).Vol.491–505.126103. Davis J.M., Chen N. Old versus new: weighing the evidence between thefirst- and second generation antipsychotics //Eur. Psychiat.- 2005. - № 20. – Рр. 7–14.104. Dufresne RL, Kass DJ, Becker RE. Bupropion and thiothixene versusplacebo and thiothixene in the treatment of depression in schizophrenia. DrugDevelopment Research. 1988. Vol.12(3-4). – P.259-266.105. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect ofquetiapine on depressive symptoms in patients with partially responsive schizophrenia.
JPsychopharmacol 2003; 17: 210-215.106. Fava M., Farabaugh A.H., Sickinger A.H. et al. Personality disorders anddepression // Psychol. Med. 2002. - Vol.32(6). P.1049–1057.107. Felmet K., Zisook,S., Kasckow J.W. Elderly Patients with Schizophreniaand Depression: Diagnosis and Treatment // Clin Schizophr Relat Psychoses.
2011. – Vol.4(4). – P.239–250.108. Fenton, W.S., McGlashan, T.H., Risk of schizophrenia in characterdisordered patients. // Am. J. Psychiatry 1989. – Vol.146(10). – P.1280– 1284.109. Fenton W.S. Depression, suicide, and suicide prevention in schizophrenia //Suicide Life Threat.
Behav. 2000. - Vol.30. - P.34–49.110. Ganesan S, Eggens I, Huizar K, Meulien D. Switching from antipsychotic toquetiapine XR treatment in patients with schizophrenia and high or low depressionsymptoms. // Eur Psychiatry. 2009. – Vol.24(1).
– P.1140.111. Goldberg SC, Schulz SC, Schulz PM. Resnick RJ, Hammer RM. Friedel RO.Borderline and schizotypal personality disorders treated with low-dose thiothixene vsplacebo. // Arch. Gerr. Psychiatry. 1986. – Vol.43. – P.680-686112. Hafner H., Loffler W., Maurer K.
et al. Depression, negative symptoms,social stagnation and social decline in the early course of schizophrenia // Acta Psychiatr.Scand. 1999. - Vol.100. - P.105–118.113. Harkavy-Friedman J.M., Restifo K., Malaspina D. et al. Suicidal behavior inschizophrenia: characteristics of individuals who had and had not attempted suicide //Am. J. Psychiatry. 1999. - Vol.156. - P.1276–1278.127114.
Hori A. Pharmacotherapy for personality disorders. // Psychiatry andClinical Neurosn'enres. 1998. – Vol.52. - P.13-19.115. Innamorati M, Baratta S, di Vittorio C et al. Atypical Antipsychotics in theTreatment of Depressive and Psychotic Symptoms in Patients with ChronicSchizophrenia // A Naturalistic Study Schizophr Res Treatment. 2013: 423205.116. Kasckow J.W., Zisook S. Co-occurring depressive symptoms in the olderpatients with schizophrenia // Drugs Aging.
2008. - Vol.25(8). - P.631–647.117. Kasper S. Treatment of depressive symptoms with quetiapine // ExpertReview of Neurotherapeutics. 2003. – Vol.3 (4). P.417–423.118. Kasper S. Quetiapine is effective against anxiety and depressive symptomsin long-term treatment of patients with schizophrenia. // Depress Anxiety 2004.
Vol.20.– P.44-47.119. Kendler KS, McGuire M, Gruenberg AM, O’Hare A, Spellman M, WalshD. The Roscommon family study: I. Methods, diagnosis of probands, and risk ofschizophrenia in relatives. // Arch Gen Psychiatry 1993. – Vol.50(7). – P.527-540.120. Keshavan M, Shad M, Soloff P, Schooler N. Efficacy and tolerability ofolanzapine in the treatment of schizotypal personality disorder. // Schizophr Res. 2004.
–Vol.71(1). – P.97-101.121. Kirli S, Çaliskan M. A comparative study of sertraline versus imipramine inpostpsychotic depressive disorder of schizophrenia. // Schizophrenia Research. 1998. –Vol.33(1–2). – P.103–111.122. Koenisberg H.W., Kaplan R.D., Gilmore M.M., Cooper A.M.Therelationship between syndrome and personality disorder in DSM-III: experience with2462 patients. // Am. J. Psychiatry. 1985. - Vol.142. – P.207-212.123. Kramer M.S., Vogel W.H., DiJohnson C. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
